APA (7th ed.) Citation

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., . . . Schmid, P. (2019). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 30(3), 405. https://doi.org/10.1093/annonc/mdy518

Chicago Style (17th ed.) Citation

Adams, S., et al. "Pembrolizumab Monotherapy for Previously Untreated, PD-L1-positive, Metastatic Triple-negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study." Annals of Oncology 30, no. 3 (2019): 405. https://doi.org/10.1093/annonc/mdy518.

MLA (9th ed.) Citation

Adams, S., et al. "Pembrolizumab Monotherapy for Previously Untreated, PD-L1-positive, Metastatic Triple-negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study." Annals of Oncology, vol. 30, no. 3, 2019, p. 405, https://doi.org/10.1093/annonc/mdy518.